7 completed, 1 terminated. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Tragara Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma. TG02, Radiation Therapy, Temozolomide - Astrocytoma, Grade III, Glioblastoma | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 71 | 2018-06-12 | 2025-11-26 |
| Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma TG02 citrate - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Completed | Tragara Pharmaceuticals, Inc. | 16 | 2012-09-01 | 2019-07-25 |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies TG02 citrate, Carfilzomib, Dexamethasone - AML, ALL | Phase 1 | Completed | Tragara Pharmaceuticals, Inc. | 120 | 2010-08-01 | 2016-05-06 |
| 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer apricoxib, Placebo, Docetaxel or Pemetrexed - Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Completed | University of Maryland, Baltimore | 109 | 2008-11-01 | 2019-10-30 |
| APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer gemcitabine, placebo, Erlotinib - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 2 | Completed | Tragara Pharmaceuticals, Inc. | 109 | 2008-08-01 | 2012-11-07 |
| APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202) apricoxib + lapatinib + capecitabine, placebo + lapatinib + capecitabine - Breast Cancer | Phase 2 | Terminated | Tragara Pharmaceuticals, Inc. | 12 | 2008-04-01 | 2012-03-15 |
| APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer apricoxib/erlotinib, erlotinib/placebo - Recurrent Non Small Cell Lung Cancer | Phase 2 | Completed | Tragara Pharmaceuticals, Inc. | 120 | 2008-04-01 | 2012-04-09 |
| Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients TG01 - Non-small Cell Lung Cancer | Phase 1 | Completed | Tragara Pharmaceuticals, Inc. | 45 | 2007-10-01 | 2010-03-17 |
Carcinoma, Non-Small-Cell Lung (3) · Astrocytoma (1) · Blast Crisis (1) · Breast Neoplasms (1) · Glioblastoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
apricoxib (4) · Erlotinib Hydrochloride (2) · 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (1) · Calcium Dobesilate (1) · Capecitabine (1) · Dexamethasone (1) · Docetaxel (1) · Gemcitabine (1) · Lapatinib (1) · Pemetrexed (1) · Radiotherapy (1) · Temozolomide (1) · carfilzomib (1)
United States (7) · Austria (1) · France (1) · Germany (1) · Netherlands (1) · Switzerland (1)
T Parrott (2) · Tracy Parrott (2) · Emilie Le Rhun (1) · Martin J Edelman (1) · Sara Zaknoen, M.D. (1) · Sara Zaknoen, MD (1)
2017 (1)